一项关于Lifileucel(肿瘤浸润淋巴细胞)在晚期黑色素瘤成人患者中的研究
一项关于 Lifileucel(肿瘤浸润淋巴细胞 [TIL])在既往接受过治疗的晚期黑色素瘤参与者中进行的 2 期、多中心、开放标签研究
This is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced melanoma
研究概览
详细说明
This is a Phase 2 study of the lifileucel treatment regimen in participants who previously received treatment for unresectable or metastatic (advanced) melanoma with 1 prior line of an anti-programmed cell death protein-1 (PD-1) or anti-programmed death ligand 1 (PD-L1) agent or whose melanoma progressed during or within ≤ 12 weeks after adjuvant anti-PD-(L)1 treatment (early relapse). Participants who have BRAF V600 mutation positive melanoma may have received or refused 1 additional prior line treatment with a BRAF inhibitor
± a MEK inhibitor
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Ontario, Canada
-
Toronto、Ontario, Canada、加拿大、M5G 2M9
- Princess Margaret Cancer Centre
-
-
Quebec, Canada
-
Montral、Quebec, Canada、加拿大、H2X 0A9
- Centre Hospitalier de l'Universite de Montreal
-
-
-
-
Queensland
-
Greenslopes、Queensland、澳大利亚、4120
- Greenslopes Private Hospital
-
-
-
-
Tennessee
-
Nashville、Tennessee、美国、37203
- Sarah Cannon Research Institute
-
-
-
-
-
London、英国、SW3 6JJ
- Royal Marsden Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Participant has a histologically or pathologically confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma.
- The participant has an ECOG performance status of 0 or 1 and an estimated life expectancy of > 6 months.
- The participant must have experienced radiographic disease progression on: 1 prior line of an anti-PD-(L)1 treatment (as a monotherapy or as part of a combination) for advanced melanoma or during or within ≤ 12 weeks after adjuvant anti-PD-(L)1 treatment (as a monotherapy or as part of a combination). Participants who have BRAF V600 mutation positive melanoma may have received 1 additional prior line of treatment with a BRAF inhibitor ± a MEK inhibitor or choose lifileucel as an alternative option to a BRAF inhibitor ± a MEK inhibitor.
- Participant is assessed as having at least one resectable lesion (or aggregate lesions) for lifileucel generation.
- Participant must have at least one measurable disease as defined by RECIST 1.1 following tumor resection.
- Participants who are > 70 years of age may be allowed to enroll after the investigator discusses with the medical monitor.
- Participants of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control.
- Participants must have adequate organ function.
- Participant is willing to receive optimal supportive care, including intensive care, from enrollment until the first post-treatment tumor assessment.
Exclusion Criteria:
- Participant has melanoma of uveal/ocular origin.
- Participant has symptomatic untreated brain metastases.
- Participant has active uveitis that requires active treatment.
- Participant has an active medical illness(es) that, in the opinion of the investigator, would pose increased risks for study participation, such as systemic infections; seizure disorders; coagulation disorders; or other active major medical illnesses of the cardiovascular, respiratory, or immune systems.
- Participant has any form of primary or acquired immunodeficiency (eg, SCID or AIDS).
- Participant had another primary malignancy within the previous 3 years (except for those that do not require treatment or were curatively treated >1 year ago, and in the judgment of the investigator do not pose a significant risk of recurrence.)
- Participant has a history of allogeneic cell or organ transplant.
- Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
Other protocol defined inclusion/exclusion criteria could apply.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Single Arm
Lifileucel |
A tumor sample is resected from each patient for lifileucel manufacturing. Patients will first receive the preparative non-myeloablative lymphodepletion (NMA-LD) regimen. They will then receive the lifileucel infusion, followed by an abbreviated course of aldesleukin.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Objective Response Rate
大体时间:12 months
|
To evaluate the efficacy of lifileucel as measured by ORR per RECIST v1.1 as assessed by the investigators |
12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Complete Response Rate
大体时间:12 months
|
To evaluate the efficacy of lifileucel as measured by CR rate per RECIST v1.1 as assessed by the investigators |
12 months
|
|
Duration of Response
大体时间:12 months
|
To evaluate the efficacy of lifileucel as measured by DOR per RECIST v1.1 as assessed by the investigators |
12 months
|
|
Disease Control Rate
大体时间:12 months
|
To evaluate the efficacy of lifileucel as measured by DCR per RECIST v1.1 as assessed by the investigators |
12 months
|
|
Progression-Free Survival
大体时间:12 months
|
To evaluate the efficacy of lifileucel as measured by PFS per RECIST v1.1 as assessed by the investigators |
12 months
|
|
Overall Survival
大体时间:18 months
|
To evaluate the efficacy of lifileucel as measured by OS |
18 months
|
|
Adverse Events
大体时间:18 months
|
To demonstrate safety and tolerability of lifileucel |
18 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- IOV-MEL-202
- 2025-522054-40-00 (克蒂斯)
- 2025 (美国 NIH 拨款/合同)
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.